Treating COVID-19 infection with molnupiravir can lead to quicker recovery at home

Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, according to the results of a randomized controlled trial, published in The Lancet journal. However, the patients treated at home with molnupiravir recovered quicker compared to the control group.